As a composite antiviral agent, Vosevi's mechanism of action involves multi-target inhibition of virus replication, while also being cautious of metabolic competition and toxicity risks with specific drugs. The following is a systematic explanation of the principle of action and key points of interaction of the drug.

1. Mechanism of action

(1) Sofosbuvir: As an NS5B polymerase inhibitor, it terminates replication by incorporating viral RNA strands.

(2) Vepatasvir: targets the NS5A protein, disrupting the assembly and function of viral replication complexes.

(3) Fosprovir: an NS3/4A protease inhibitor that blocks the processing of multiple protein precursors.

2. Drug interactions

2.1 Effects of Metabolic Enzymes

(1) CYP3A4 inducers (such as rifampicin): may significantly reduce the blood concentration of sofosbuvir and should be avoided in combination.

(2) P-gp transporter inhibitors (such as amiodarone): may increase exposure to Vepatasvir and increase the risk of adverse reactions.

2.2 Typical interacting drugs

(1) Antacids (aluminum/magnesium preparations): should be taken every 4 hours to avoid reducing the absorption rate of sofosbuvir.

(2) H2 receptor blockers: It is recommended to administer them 12 hours apart to prevent an increase in gastric pH from affecting drug dissolution.

(3) St. John's Wort: Inducing CYP3A4/P-gp to reduce the efficacy of Jisi generation by more than 50%, absolutely contraindicated.

2.3 Special Risk Portfolio

(1) Amiodarone: Combination use may cause symptomatic bradycardia, requiring electrocardiographic monitoring.

(2) Tacrolimus: Blood drug concentration needs to be monitored, and Jisi Dai may increase its AUC by up to three times.

(3) Antiepileptic drugs (carbamazepine): Non enzymatic inducers should be used to avoid treatment failure.